In This Article:
OSE Immunotherapeutics Highlights Abstracts Selected for
Presentation at ASCO 2025
Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim
NANTES, France – April 23, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that several abstracts highlighting the Company's innovative assets have been selected for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 1-5, 2025, in Chicago, Illinois.
The abstracts feature both proprietary and partnered assets, showcasing OSE Immunotherapeutics' commitment to advancing cancer treatment through cutting-edge research and strategic collaborations addressing multiple cancer types.
Highlights:
-
Proprietary Asset: Tedopi® (OSE-2101) cancer vaccine: Trial in Progress for ARTEMIA Phase 3 trial in Non-Small Cell Lung Cancer; Oral Presentation for TEDOPaM Phase 2 trial topline results in pancreatic cancer, presented by the study’s sponsor GERCOR Group.
-
Partnered Assets: SIRPα antagonists BI 765063 and BI 770371, an improved next generation SIRPα inhibitor, developed in partnership with Boehringer Ingelheim: Rapid Oral Abstracts of the Phase 1 results for BI 765063 and BI 770371 presented by Boehringer Ingelheim, OSE Immunotherapeutics’ partner.
| Tedopi® (OSE-2101) cancer vaccine in ARTEMIA Phase 3 trial – OSE IMMUNOTHERAPEUTICS | |
| Abstract Number | TPS8651 |
| Title | “Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy” |
| Session Type and Title | Poster Session – Lung Cancer — Non-Small Cell Metastatic |
| Date and time | May 31, 2025 - 1:30 PM - 4:30 PM CDT |
| Tedopi® (OSE-2101) cancer vaccine in TEDOPaM Phase 2 trial – OSE IMMUNOTHERAPEUTICS | |
| Abstract Number | 4009 |
| Title | “Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial” |
| Session Type and Title | Clinical Science Symposium – Innovative Biomarkers and Vaccines in Pancreatic Cancer Session |
| Date and time | June 2, 2025 - 8:00 AM - 9.30 AM CDT |
| BI 770371 – Phase 1 trial - BOEHRINGER INGELHEIM | |
| Abstract Number | 2515 |
| Title | “An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with ezabenlimab in patients with advanced solid tumors” |
| Session Type and Title | Rapid Oral Abstract - Developmental Therapeutics - Immunotherapy |
| Date and time | June 1, 2025 - 11:15 AM - 12:45:PM CDT |
| BI 765063 – Phase 1b trial - BOEHRINGER INGELHEIM | |
| Abstract Number | 6019 |
| Title | “An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma” |
| Session Type and Title | Rapid Oral Abstract - Head and Neck Cancer |
| Date and time | June 1, 2025 - 11:30 AM - 1:30 PM CDT |
The abstract summaries will be available on ASCO website on Thursday, May 22, 2025.